Clarithromycin的体内抗菌作用研究

Study on the in vivo antimicrobial activities of clarithromycin

新的１４元大环内酯ｃｌａｒｉｔｈｒｏｍｙｃｉｎ（ＣＲＭ）与红霉素（ＥＭ）对金葡球菌、化脓链球菌、肺炎链球菌、嗜血流感杆菌感染小鼠体内保护作用结果显示：口服ＣＲＭ对金葡球菌、化脓链球菌及肺炎链球菌的体内抗菌作用优于ＥＭ６．３～８．６倍。尤其对金葡球菌耐药菌及嗜血流感杆菌感染小鼠的半数保护剂量作用有效于ＥＭ的保护作用１７及１８倍，ＣＲＭ在体内具有良好的抗菌作用。

In this paper,the in vivo protection activities of a new 14-membered macrolide, clarithromycin against Staphylococci aureus,Streptococcus pyogenes and Streptococcus pneumoniae infection were compared with that of erythromycin .Results showed that clarithromycin is 6.3～8. 6 times more protent than erythromycin when administered orally in mouse protection test against Staphylococci aureus ,Streptococcus pyogenes and Streptococcus pneumoniae. Especially clarithromycin's 50% effective dose is more protent about 17and 18 times than erythromycin against Staphylococci aureus resistant strains and Haemophilas irfluenze. Results showed clarithromycin is a very effective antibacterial agent.